Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R.

N Engl J Med. 2003 Jul 31;349(5):446-56.

3.

Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.

Joy MS, Karagiannis PC, Peyerl FW.

J Manag Care Pharm. 2007 Jun;13(5):397-411. Review.

4.

Interventions for metabolic bone disease in children with chronic kidney disease.

Hahn D, Hodson EM, Craig JC.

Cochrane Database Syst Rev. 2015 Nov 12;(11):CD008327. doi: 10.1002/14651858.CD008327.pub2. Review.

PMID:
26561037
5.

Vitamin D analogues for the management of secondary hyperparathyroidism.

Martin KJ, González EA.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34-40. Review.

PMID:
11689385
6.

Impact of kidney bone disease and its management on survival of patients on dialysis.

Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K.

J Ren Nutr. 2007 Jan;17(1):38-44. Review.

PMID:
17198930
8.

Strategies to minimize bone disease in renal failure.

Martin KJ, González EA.

Am J Kidney Dis. 2001 Dec;38(6):1430-6. Review.

PMID:
11728986
9.

Are new vitamin D analogues in renal bone disease superior to calcitriol?

Salusky IB.

Pediatr Nephrol. 2005 Mar;20(3):393-8. Review.

PMID:
15690188
10.

Spotlight on paricalcitol in secondary hyperparathyroidism.

Robinson DM, Scott LJ.

Treat Endocrinol. 2005;4(3):185-6. Review.

PMID:
15898824
11.

Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.

Donate-Correa J, Domínguez-Pimentel V, Muros-de-Fuentes M, Mora-Fernández C, Martín-Núñez E, Cazaña-Pérez V, Navarro-González JF.

Curr Drug Targets. 2014;15(7):703-9. Review.

PMID:
24745821
12.

[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].

Bover J, Ballarín J, Andrés E, Ortiz-Herbener F, Barceló P.

Nefrologia. 2005;25 Suppl 2:109-16. Review. Spanish.

13.

Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.

Rosery H, Bergemann R, Marx SE, Boehnke A, Melnick J, Sterz R, Williams L.

Clin Drug Investig. 2006;26(11):629-38. Review.

PMID:
17163297
14.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
16.

Vitamin D compounds for people with chronic kidney disease requiring dialysis.

Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005633. doi: 10.1002/14651858.CD005633.pub2. Review.

PMID:
19821349
18.

Use of vitamin D analogs in chronic renal failure.

Kim G, Sprague SM.

Adv Ren Replace Ther. 2002 Jul;9(3):175-83. Review.

PMID:
12203199
19.

Target levels for serum phosphorus and parathyroid hormone.

Qunibi W, Kalantar-Zadeh K.

Semin Dial. 2011 Jan-Feb;24(1):29-33. doi: 10.1111/j.1525-139X.2010.00823.x. Review. No abstract available.

PMID:
21324001
20.

Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward.

Wolf M, Thadhani R.

J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):487-90. Review.

Supplemental Content

Support Center